These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 37574391)

  • 1. Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
    Shore N; Gazi M; Pieczonka C; Heron S; Modh R; Cahn D; Belkoff LH; Berger A; Mazzarella B; Veys J; Idom C; Morris D; Jayram G; Engelman A; Bukkapatnam R; Dato P; Bevan-Thomas R; Cornell R; Wise DR; Hardwick MK; Hernandez RD; Rojahn S; Layman P; Hatchell KE; Heald B; Nussbaum RL; Nielsen SM; Esplin ED
    Eur Urol Oncol; 2023 Oct; 6(5):477-483. PubMed ID: 37574391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer.
    Heald B; Mokhtary S; Nielsen SM; Rojahn S; Yang S; Michalski ST; Esplin ED
    Gynecol Oncol; 2022 Aug; 166(2):344-350. PubMed ID: 35691755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline Pathogenic Variants Identified in Patients With Genitourinary Malignancies Undergoing Universal Testing: A Multisite Single-Institution Prospective Study.
    Choudry MM; Durant AM; Edmonds VS; Warren CJ; Kunze KL; Golafshar MA; Nielsen SM; Esplin ED; Andrews JR; Samadder NJ; Tyson MD
    J Urol; 2024 Jun; ():101097JU0000000000004089. PubMed ID: 38860938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addition of Germline Testing to Tumor-Only Sequencing Improves Detection of Pathogenic Germline Variants in Men With Advanced Prostate Cancer.
    Berchuck JE; Boiarsky D; Silver R; Sunkara R; McClure HM; Tsai HK; Siegmund S; Tewari AK; Nowak JA; Lindeman NI; Rana HQ; Choudhury AD; Pomerantz MM; Freedman ML; Van Allen EM; Taplin ME
    JCO Precis Oncol; 2022 Aug; 6():e2200329. PubMed ID: 36103646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study.
    Arrieta O; Caballé-Pérez E; Hernández-Pedro N; Romero-Nuñez E; Lucio-Lozada J; Castillo-Ruiz C; Acevedo-Castillo K; María Álvarez-Gómez R; Molina-Garay C; Jiménez-Olivares M; Carrillo-Sánchez K; Cristina Mendoza-Caamal E; Cardona AF; Remon J; Alaez-Verson C
    Lung Cancer; 2024 Jun; 194():107864. PubMed ID: 38945003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility and Clinical Utility of Reporting Hereditary Cancer Predisposition Pathogenic Variants Identified in Research Germline Sequencing: A Prospective Interventional Study.
    Hutchcraft ML; Zhang S; Lin N; Pickarski JC; Belcher EA; Wei S; Bocklage T; Miller RW; Villano JL; Cavnar MJ; Kim J; Arnold SM; Ueland FR; Kolesar JM
    JCO Precis Oncol; 2024 Jan; 8():e2300266. PubMed ID: 38295319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Universal Genetic Testing vs. Guideline-Directed Testing for Hereditary Cancer Syndromes Among Traditionally Underrepresented Patients in a Community Oncology Program.
    Jones JC; Golafshar MA; Coston TW; Rao R; Wysokinska E; Johnson E; Esplin ED; Nussbaum RL; Heald B; Klint M; Barrus K; Uson PL; Nguyen CC; Colon-Otero G; Bekaii-Saab TS; Dronca R; Kunze KL; Samadder NJ
    Cureus; 2023 Apr; 15(4):e37428. PubMed ID: 37181954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
    Rebhan K; Stelzer PD; Pradere B; Rajwa P; Kramer G; Hofmann B; Resch I; Yurdakul O; Laccone FA; Bujalkova MG; Smogavec M; Tan YY; Ristl R; Shariat SF; Egger G; Hassler MR
    World J Urol; 2023 Aug; 41(8):2091-2097. PubMed ID: 37528288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Universal Genetic Testing vs Guideline-Directed Targeted Testing for Patients With Hereditary Cancer Syndrome.
    Samadder NJ; Riegert-Johnson D; Boardman L; Rhodes D; Wick M; Okuno S; Kunze KL; Golafshar M; Uson PLS; Mountjoy L; Ertz-Archambault N; Patel N; Rodriguez EA; Lizaola-Mayo B; Lehrer M; Thorpe CS; Yu NY; Esplin ED; Nussbaum RL; Sharp RR; Azevedo C; Klint M; Hager M; Macklin-Mantia S; Bryce AH; Bekaii-Saab TS; Sekulic A; Stewart AK
    JAMA Oncol; 2021 Feb; 7(2):230-237. PubMed ID: 33126242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Yield and Utility of Germline Testing Following Tumor Sequencing in Patients With Cancer.
    Lincoln SE; Nussbaum RL; Kurian AW; Nielsen SM; Das K; Michalski S; Yang S; Ngo N; Blanco A; Esplin ED
    JAMA Netw Open; 2020 Oct; 3(10):e2019452. PubMed ID: 33026450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
    Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
    Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
    Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
    Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study.
    Uson PLS; Riegert-Johnson D; Boardman L; Kisiel J; Mountjoy L; Patel N; Lizaola-Mayo B; Borad MJ; Ahn D; Sonbol MB; Jones J; Leighton JA; Gurudu S; Singh H; Klint M; Kunze KL; Golafshar MA; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab TS; Jewel Samadder N
    Clin Gastroenterol Hepatol; 2022 Mar; 20(3):e508-e528. PubMed ID: 33857637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Germline Genetic Testing in Unselected Squamous and Non-Squamous Head and Neck Cancers.
    Brake DA; Idler BM; Kunze KL; Golafshar MA; Heald B; Young S; Klint M; Barrus K; Esplin ED; Nussbaum RL; Samadder NJ; Hinni ML; Chang BA
    Laryngoscope; 2023 Dec; 133(12):3378-3388. PubMed ID: 37132629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Extended gene panel testing in lobular breast cancer.
    van Veen EM; Evans DG; Harkness EF; Byers HJ; Ellingford JM; Woodward ER; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
    Fam Cancer; 2022 Apr; 21(2):129-136. PubMed ID: 33763779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma.
    Brand R; Borazanci E; Speare V; Dudley B; Karloski E; Peters MLB; Stobie L; Bahary N; Zeh H; Zureikat A; Hogg M; Lee K; Tsung A; Rhee J; Ohr J; Sun W; Lee J; Moser AJ; DeLeonardis K; Krejdovsky J; Dalton E; LaDuca H; Dolinsky J; Colvin A; Lim C; Black MH; Tung N
    Cancer; 2018 Sep; 124(17):3520-3527. PubMed ID: 30067863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline Genetic Mutations in Adult Patients with Sarcoma: Insight into the Middle East Genetic Landscape.
    Abu-Hijlih R; Sharaf B; Salah S; Bani Hani H; Alqaisieh M; Alzibdeh A; Ababneh L; Mahafdah S; Abdel-Razeq H
    Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal Germline Testing of Unselected Cancer Patients Detects Pathogenic Variants Missed by Standard Guidelines without Increasing Healthcare Costs.
    Perkins AT; Haslem D; Goldsberry J; Shortt K; Sittig L; Raghunath S; Giauque C; Snow S; Fulde G; Moulton B; Jones D; Nadauld L
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rate of Pathogenic Germline Variants in Patients With Lung Cancer.
    Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
    JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.